Clozapine Effektif pada Pasien Skizofrenia yang Resisten terhadap Pengobatan

Natasha Syifa Rachman, Dede Setiapriagung, Siti Annisa Devi Trusda

Abstract


Abstract. Schizophrenia is a neuropsychiatric disorder with a high morbidity rate. One of the therapies to treat schizophrenic patients is to use antipsychotics such as typical and atypical drugs. Typical antipsychotics are the first line of treatment for schizophrenia but recently resistance is often developed, so that therapy is switched to atypical antipsychotics. Clozapine is the most commonly used atypical antipsychotic. The aim of this study was to determine the effectiveness of clozapine in schizophrenic patients who were resistant to other antipsychotics. . The method used in this study is a scoping review, with research articles from international journals that meet the inclusion and exclusion criteria. This article was then selected using the PRISMA diagram by considering Population (schizophrenic patients), Intervention (giving clozapine), Comparison (placebo or other antipsychotic), Outcome (reduction in psychotic symptoms), Study (RCT, clinical trial, case report, and meta analysis) . The results of this study indicate that clozapine is one of the most effective atypical antipsychotics compared to other antipsychotic drugs to treat patients suffering from schizophrenia, especially for schizophrenic patients who are resistant to other antipsychotic treatments.

Keywords : Atypical Antipsychotic, Clozapine, Schizophrenia, Typical Antipsychotic, resistant

Abstrak. Skizofrenia merupakan gangguan neuropsikiatik dengan angka morbiditas yang masih tinggi. Salah satu terapi untuk menangani pasien skizofrenia adalah dengan menggunakan antipsikotik berupa tipikal dan atipikal. Antipsikotik tipikal menjadi lini pertama pengobatan skizofrenia. Dewasa ini berkembang penelitian bahwa sering terjadi resistensi terhadap antipsikotik tipikal, sehingga terapi beralih ke antipsikotik atipikal. Clozapine merupakan antipsikotik atipikal yang paling sering digunakan. Tujuan penelitian ini  adalah mengetahui efektifitas clozapine terhadap pasien skizofrenia yang resisten terhadap antipsikotik lain.  Metoda yang digunakan dalam penelitian ini adalah scoping review, dengan bahan penelitian artikel dari jurnal internasional yang memenuhi kriteria inklusi dan eksklusi. Artikel ini kemudian diseleksi menggunakan diagram PRISMA dengan mempertimbangkan Population (pasien skizofrenia), Intervention (pemberian clozapine), Comparison (plasebo atau antipsikotik lain), Outcome (penurunan gejala psikotik), Study (RCT, clinical trial, case report, dan meta analysis ). Hasil penelitian ini menunjukan bahwa clozapine merupakan salah satu antipsikotik atipikal yang paling efektif dibandingkan dengan obat antipsikotik lainnya untuk mengobati pasien yang menderita skizofrenia, khususnya untuk pasien skizofrenia yang resisten terhadap pengobatan antipsikotik lain.

Kata Kunci : Antipsikotik Atipikal, Antipsikotik Tipikal, Clozapine, Skizofrenia, Resisten


Keywords


Antipsikotik Atipikal, Antipsikotik Tipikal, Clozapine, Skizofrenia, Resisten

References


Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203.

Ayano G, Duko B. Relapse and hospitalization in patients with schizophrenia and bipolar disorder at the St Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: A comparative quantitative cross-sectional study. Neuropsychiatr Dis Treat. 2017;13:1527–31.

Van Zelst C. Stigmatization as an environmental risk in schizophrenia: A user perspective. Schizophr Bull. 2009;35(2):293–6.

Agarwal G, Pirigyi M, Meltzer H. Schizophrenia and Suicide: Treatment Optimization. Curr Treat Options Psychiatry. 2014;1(2):149–62.

Kasckow J, Felmet K, Zisook S. Managing suicide risk in patients with schizophrenia. CNS Drugs. 2011;25(2):129–43.

Ventriglio A, Gentile A, Bonfitto I, Stella E, Mari M, Steardo L, et al. Suicide in the early stage of schizophrenia. Front Psychiatry. 2016;7(JUN):1–9.

Wimberley T, MacCabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 2017;174(10):990–8.

Solmi M, Murru A, Pacchiarotti I, Veronese N. TCRM-117321-the-safety--tolerability--and-risks-associated-with-first--a. Ther Clin Risk Manag [Internet]. 2017;(13):757–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499790/pdf/tcrm-13-757.pdf

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–27.

Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154(4 SUPPL.):1–63.

Vita A, Minelli A, Barlati S, Deste G, Giacopuzzi E, Valsecchi P, et al. Treatment-resistant schizophrenia: Genetic and neuroimaging correlates. Front Pharmacol. 2019;10(APR):1–16.

Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry. 2003;182(JUNE):505–8.

de Araújo AN, de Sena EP, de Oliveira IR, Juruena MF. Antipsychotic agents: Efficacy and safety in schizophrenia. Drug Healthc Patient Saf. 2012;4(1):173–80.

Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619–29.

Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis. J Clin Psychopharmacol. 2012;32(3):309–16.

Raja M. Clinical Medicine : Therapeutics pharmacotherapy Update : Risperidone in the Treatment of schizophrenia. :1199–214.

Surv Surveillance eillance report 2017 – Psoriasis : assessment and management (2012) NICE guideline CG153. 2017;(June).

Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210.

Curry B, Palmer E, Mounce C, Smith G, Shah V. Assessing prescribing practices of clozapine before and after the implementation of an updated risk evaluation and mitigation strategy. Ment Heal Clin. 2018;8(2):63–7.

Khan AH, Zaidi S. Clozapine: Improvement of Negative Symptoms of Schizophrenia. Cureus. 2017;9(12).

Amir, Weber, Beard, Bomyea T. 基因的改变NIH Public Access. Bone [Internet]. 2008;23(1):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf

Correll CU, Brevig T, Brain C. Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists. Neuropsychiatr Dis Treat. 2019;15:3461–73.

Menkes DB, Glue P, Gale C, Lam F, Hung CT, Hung N. Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients. EBioMedicine [Internet]. 2018;27:134–7. Available from: https://doi.org/10.1016/j.ebiom.2017.11.030

Every-Palmer S, Inns SJ, Ellis PM. Constipation screening in people taking clozapine: A diagnostic accuracy study. Schizophr Res [Internet]. 2020;220:179–86. Available from: https://doi.org/10.1016/j.schres.2020.03.032




DOI: http://dx.doi.org/10.29313/kedokteran.v7i1.26839

Flag Counter